Review

Breast cancer risk evaluation for the primary care physician

Christine L. Klassen, MD, Elizabeth Gilman, MD, Aparna Kaur, MD, Sara P. Lester, MD and Sandhya Pruthi, MD
Cleveland Clinic Journal of Medicine March 2022, 89 (3) 139-146; DOI: https://doi.org/10.3949/ccjm.89a.21023

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    Systematic approach to breast cancer risk evaluation. A step-by-step approach to categorize patients who require further stratification vs patients needing referral to breast specialist.

    ATM = arabidopsis thaliana homeobox gene 1; BCRAT = Breast Cancer Risk Assessment Tool; BMI = body mass index; BRCA = BReast CAncer gene; CEM = contrast-enhanced mammogram; CHEK = checkpoint kinase 2; IBIS = International Breast Intervention Study; LCIS = lobular carcinoma in situ; MBI = molecular breast imaging; MRI = magnetic resonance imaging; NBN = nibrin; NCI = National Cancer Institute; NF1 = neurofibromin; PALB = partner and localizer of BRCA; PTEN = phosphatase and tensin homolog; STK = serine/threonine kinase; TNBC = triple-negative breast cancer; TP = tumor protein; US = ultrasonography

    Data from references 6, 7, 9, 11, 29, and 31.

Tables

  • TABLE 1

    Annual breast cancer case distribution by age

    Age range (years)New breast cancer cases, %
    20–341.9%
    35–448.2%
    45–5419.2%
    55–6425.6%
    65–7426%
    75–8413.7%
    > 845.4%

    • Data from reference 16.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects